Pulmazole phase 2 clinical study gets FDA approval for Pulmazole in allergic bronchopulmonary aspergillosis
Pulmatrix, the Massachusetts-based biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to initiate a phase 2 clinical trial for Pulmazole (PUR1900). This drug candidate is targeted at treating allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The approval follows a successful review of Pulmatrix’s Investigational New Drug (IND) application by […]